Wayland, Mass. — The Ellipse™ Flex IPL (intense pulsed light) system, developed by Wayland-based Candela Corp., has earned clearance from the Food and Drug Administration.
According to Candela, the Ellipse Flex IPL was developed in cooperation with dermatologists and skin researchers. The device is intended for various cosmetic treatments and applications, such as facial rejuvenation, vascular lesions, facial veins, acne, age spots and diffuse redness.
The company says the Ellipse Flex IPL features a programmable pulse mode, which allows the user to “customize” pulse output to each individual patient’s particular clinical needs. The device also includes “Dual-Mode Filtering” technology, a patented feature that removes potentially harmful water-absorbing wavelengths from the output spectrum. This technology, according to Candela, decreases the risk of side effects.
